Key result
Isoproterenol increased heparin-releasable lipoprotein lipase activity only during conditions of increased cardiac workload, likely via an AMPK-dependent mechanism.
Why the study?
Does isoproterenol influence cardiac lipoprotein lipase activity in preclinical models?
Population
Preclinical models including quiescent cardiomyocytes, Langendorff isolated hearts, intact animals, and…
Comparison
Isoproterenol administration vs Baseline or control conditions
Design
Preclinical
Authors
Loading...
Isoproterenol may boost cardiac LPL under high workload in rodents; leaves open whether AMPK mediates similar effects in human heart disease.
Does isoproterenol influence cardiac lipoprotein lipase activity in preclinical models?
Beta-agonist stimulation with isoproterenol increases cardiac lipoprotein lipase activity only during conditions of increased workload, likely mediated by AMPK activation.
Ding et al. (2005) studied this question. Isoproterenol was evaluated on Cardiac lipoprotein lipase (LPL) activity. Isoproterenol increased heparin-releasable lipoprotein lipase activity only during conditions of increased cardiac workload, likely via an AMPK-dependent mechanism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: